477 related articles for article (PubMed ID: 31356921)
1. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis.
Pavel AB; Song T; Kim HJ; Del Duca E; Krueger JG; Dubin C; Peng X; Xu H; Zhang N; Estrada YD; Denis L; Rao N; Gupta S; Zammit DJ; Bissonnette R; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Oct; 144(4):1011-1024. PubMed ID: 31356921
[TBL] [Abstract][Full Text] [Related]
2. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Bissonnette R; Maari C; Forman S; Bhatia N; Lee M; Fowler J; Tyring S; Pariser D; Sofen H; Dhawan S; Zook M; Zammit DJ; Usansky H; Denis L; Rao N; Song T; Pavel AB; Guttman-Yassky E
Br J Dermatol; 2019 Oct; 181(4):733-742. PubMed ID: 30919407
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E; Bissonnette R; Ungar B; Suárez-Fariñas M; Ardeleanu M; Esaki H; Suprun M; Estrada Y; Xu H; Peng X; Silverberg JI; Menter A; Krueger JG; Zhang R; Chaudhry U; Swanson B; Graham NMH; Pirozzi G; Yancopoulos GD; D Hamilton JD
J Allergy Clin Immunol; 2019 Jan; 143(1):155-172. PubMed ID: 30194992
[TBL] [Abstract][Full Text] [Related]
4. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.
Zhou L; Leonard A; Pavel AB; Malik K; Raja A; Glickman J; Estrada YD; Peng X; Del Duca E; Sanz-Cabanillas J; Ruano J; Xu H; Zhang N; Wen HC; Gonzalez J; Garcet S; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Jul; 144(1):144-156. PubMed ID: 30685456
[TBL] [Abstract][Full Text] [Related]
5. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities.
He H; Del Duca E; Diaz A; Kim HJ; Gay-Mimbrera J; Zhang N; Wu J; Beaziz J; Estrada Y; Krueger JG; Pavel AB; Ruano J; Guttman-Yassky E
J Allergy Clin Immunol; 2021 Apr; 147(4):1369-1380. PubMed ID: 33011244
[TBL] [Abstract][Full Text] [Related]
6. Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis.
Guttman-Yassky E; Diaz A; Pavel AB; Fernandes M; Lefferdink R; Erickson T; Canter T; Rangel S; Peng X; Li R; Estrada Y; Xu H; Krueger JG; Paller AS
JAMA Dermatol; 2019 Dec; 155(12):1358-1370. PubMed ID: 31596431
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.
Suárez-Fariñas M; Dhingra N; Gittler J; Shemer A; Cardinale I; de Guzman Strong C; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2013 Aug; 132(2):361-70. PubMed ID: 23777851
[TBL] [Abstract][Full Text] [Related]
9. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
[TBL] [Abstract][Full Text] [Related]
10. Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial.
Czarnowicki T; Dohlman AB; Malik K; Antonini D; Bissonnette R; Chan TC; Zhou L; Wen HC; Estrada Y; Xu H; Bryson C; Shen J; Lala D; Ma'ayan A; McGeehan G; Gregg R; Guttman-Yassky E
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):631-640.e11. PubMed ID: 29567358
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.
Khattri S; Shemer A; Rozenblit M; Dhingra N; Czarnowicki T; Finney R; Gilleaudeau P; Sullivan-Whalen M; Zheng X; Xu H; Cardinale I; de Guzman Strong C; Gonzalez J; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2014 Jun; 133(6):1626-34. PubMed ID: 24786238
[TBL] [Abstract][Full Text] [Related]
12. JAK Inhibitors for Atopic Dermatitis: An Update.
He H; Guttman-Yassky E
Am J Clin Dermatol; 2019 Apr; 20(2):181-192. PubMed ID: 30536048
[TBL] [Abstract][Full Text] [Related]
13. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
Bissonnette R; Pavel AB; Diaz A; Werth JL; Zang C; Vranic I; Purohit VS; Zielinski MA; Vlahos B; Estrada YD; Saint-Cyr Proulx E; Ports WC; Guttman-Yassky E
J Allergy Clin Immunol; 2019 Nov; 144(5):1274-1289. PubMed ID: 31419544
[TBL] [Abstract][Full Text] [Related]
14. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults.
Renert-Yuval Y; Del Duca E; Pavel AB; Fang M; Lefferdink R; Wu J; Diaz A; Estrada YD; Canter T; Zhang N; Wagner A; Chamlin S; Krueger JG; Guttman-Yassky E; Paller AS
J Allergy Clin Immunol; 2021 Jul; 148(1):148-163. PubMed ID: 33453290
[TBL] [Abstract][Full Text] [Related]
15. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing.
Suárez-Fariñas M; Ungar B; Noda S; Shroff A; Mansouri Y; Fuentes-Duculan J; Czernik A; Zheng X; Estrada YD; Xu H; Peng X; Shemer A; Krueger JG; Lebwohl MG; Guttman-Yassky E
J Allergy Clin Immunol; 2015 Nov; 136(5):1277-87. PubMed ID: 26316095
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.
Khattri S; Brunner PM; Garcet S; Finney R; Cohen SR; Oliva M; Dutt R; Fuentes-Duculan J; Zheng X; Li X; Bonifacio KM; Kunjravia N; Coats I; Cueto I; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
Exp Dermatol; 2017 Jan; 26(1):28-35. PubMed ID: 27304428
[TBL] [Abstract][Full Text] [Related]
17. Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis.
Hulshof L; Overbeek SA; Wyllie AL; Chu MLJN; Bogaert D; de Jager W; Knippels LMJ; Sanders EAM; van Aalderen WMC; Garssen J; Van't Land B; Sprikkelman AB;
Front Immunol; 2018; 9():630. PubMed ID: 29966024
[TBL] [Abstract][Full Text] [Related]
18. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin.
Pavel AB; Renert-Yuval Y; Wu J; Del Duca E; Diaz A; Lefferdink R; Fang MM; Canter T; Rangel SM; Zhang N; Krueger JG; Paller AS; Guttman-Yassky E
Allergy; 2021 Jan; 76(1):314-325. PubMed ID: 32639640
[TBL] [Abstract][Full Text] [Related]
19. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.
Brunner PM; Khattri S; Garcet S; Finney R; Oliva M; Dutt R; Fuentes-Duculan J; Zheng X; Li X; Bonifacio KM; Kunjravia N; Coats I; Cueto I; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
J Allergy Clin Immunol; 2016 Jul; 138(1):169-178. PubMed ID: 26948076
[TBL] [Abstract][Full Text] [Related]
20. Early-onset pediatric atopic dermatitis is T
Esaki H; Brunner PM; Renert-Yuval Y; Czarnowicki T; Huynh T; Tran G; Lyon S; Rodriguez G; Immaneni S; Johnson DB; Bauer B; Fuentes-Duculan J; Zheng X; Peng X; Estrada YD; Xu H; de Guzman Strong C; Suárez-Fariñas M; Krueger JG; Paller AS; Guttman-Yassky E
J Allergy Clin Immunol; 2016 Dec; 138(6):1639-1651. PubMed ID: 27671162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
